450 Brookline Avenue
Boston, MA 02215
United States
Cholangiocarcinoma; IDH1 mutation; Ivosidenib; Phase 3 study
Refractory metastatic colorectal cancer, Regorafenib, Dose-optimization, Phase 2, Dosing strategies